Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -18.48% is 24% above its 5-year average of -24.43%, near the high end of its 5-year range (-70.07%–-6.08%).
58.52% below its 12-month average of -11.66%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -6.35%.
OPERATING MARGIN
-18.48%
OPERATING MARGIN AVG TTM
-11.66%
OPERATING MARGIN AVG 3Y
-28.60%
OPERATING MARGIN AVG 5Y
-24.43%
OPERATING MARGIN AVG 10Y
-30.36%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-58.52%
CURRENT VS 3Y AVG
+35.38%
CURRENT VS 5Y AVG
+24.36%
CURRENT VS 10Y AVG
+39.13%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Establishment Labs Holdings Inc.
Market Cap
$1.92B
Operating Margin
-18.48%
TTM Avg
-11.66%
3Y Avg
-28.60%
5Y Avg
-24.43%
Market Cap
$1.94B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.89B
Operating Margin
-873.87%
TTM Avg
-1020.17%
3Y Avg
-1557.98%
5Y Avg
-1038.65%
Market Cap
$1.95B
Operating Margin
-5.12%
TTM Avg
-2.62%
3Y Avg
-10.04%
5Y Avg
-13.46%
Market Cap
$1.89B
Operating Margin
-87.33%
TTM Avg
-133.51%
3Y Avg
-104.25%
5Y Avg
-284.42%
Market Cap
$1.96B
Operating Margin
-682.68%
TTM Avg
-736.97%
3Y Avg
-554.11%
5Y Avg
-436.61%
Market Cap
$1.89B
Operating Margin
-1.12%
TTM Avg
-4.89%
3Y Avg
-11.52%
5Y Avg
-13.12%
Market Cap
$1.97B
Operating Margin
6.02%
TTM Avg
5.04%
3Y Avg
-2.01%
5Y Avg
-12.30%
Market Cap
$1.87B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.92B | -18.48% | -11.66% | -28.60% | -24.43% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | 0.00% | 0.00% | 0.00% | 0.00% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -873.87% | -1020.17% | -1557.98% | -1038.65% |
| AxoGen, Inc. (AXGN)vs › | $1.95B | -5.12% | -2.62% | -10.04% | -13.46% |
| Zymeworks Inc. (ZYME)vs › | $1.89B | -87.33% | -133.51% | -104.25% | -284.42% |
| Vir Biotechnology, Inc. (VIR)vs › | $1.96B | -682.68% | -736.97% | -554.11% | -436.61% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | -1.12% | -4.89% | -11.52% | -13.12% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 6.02% | 5.04% | -2.01% | -12.30% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | 0.00% | 0.00% | 0.00% | 0.00% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | 0.41% | -3.56% | 0.15% | -1.31% |
Gross Margin
70.5%
Operating Margin
-18.5%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -6.35% |
| 2026-03-31 | -10.87% |
| 2025-12-31 | -6.08% |
| 2025-09-30 | -7.48% |
| 2025-06-30 | -27.50% |
| 2025-03-31 | -40.96% |
| 2024-12-31 | -41.94% |
| 2024-09-30 | -32.66% |
| 2024-06-30 | -21.18% |
| 2024-03-31 | -23.77% |
| 2023-12-31 | -70.07% |
| 2023-09-30 | -54.64% |
| 2023-06-30 | -28.24% |
| 2023-03-31 | -17.54% |
| 2022-12-31 | -30.04% |
| 2022-09-30 | -27.50% |
| 2022-06-30 | -25.26% |
| 2022-03-31 | -14.50% |
| 2021-12-31 | -26.52% |
| 2021-09-30 | -31.14% |
| 2021-06-30 | -14.48% |
| 2021-03-31 | -6.91% |
| 2020-12-31 | -29.73% |
| 2020-09-30 | -11.39% |
| 2020-06-30 | -91.68% |
| 2020-03-31 | -31.47% |
| 2019-12-31 | -18.17% |
| 2019-09-30 | -38.35% |
| 2019-06-30 | -43.27% |
| 2019-03-31 | -40.37% |
| 2018-12-31 | -52.58% |
| 2018-09-30 | -37.12% |
| 2018-06-30 | -46.08% |
| 2018-03-31 | -19.44% |
| 2017-12-31 | -38.85% |
| 2017-09-30 | -81.53% |
| 2017-06-30 | -63.54% |
| 2017-03-31 | -56.97% |
